Inozyme
Biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $270m Valuation: $270m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 3292 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (9457 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (9377 %) | (270 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Inozyme Pharma is a biopharmaceutical company focused on developing innovative treatments for rare diseases characterized by abnormal mineralization, which affects the vasculature, soft tissue, and skeleton. The company primarily targets genetic conditions such as ENPP1 deficiency and ABCC6 deficiency, which lead to severe and often life-threatening complications. Inozyme's lead product candidate, INZ-701, aims to restore the balance of pyrophosphate (PPi) and adenosine, addressing the root causes of these deficiencies. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutics. Revenue is generated through the successful development and sale of these specialized treatments. Inozyme operates in the rare disease market, serving patients, healthcare providers, and medical researchers. The company is headquartered in Boston, MA, and collaborates with scientists, physicians, and patients to bring its therapies to market.
Keywords: biopharmaceutical, rare diseases, abnormal mineralization, ENPP1 deficiency, ABCC6 deficiency, INZ-701, pyrophosphate, adenosine, vasculature, soft tissue.